Tizanidine is an effective agent in the prevention of focal cerebral ischemia in rats: An experimental study

Surgical Neurology

Volumn 50, Issue 3, 1998, Pages 264-271

  Berkman, M Zafer ^a,c   Zirh, T Ali ^b   Berkman, Kemal ^b   Pamir, M Necmettin ^b  

^a OKMEYDANI EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^b MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^c NONE   (Turkey)

Author keywords

Focal cerebral ischemia; Middle cerebral artery; Reperfusion; Tizanidine

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; TIZANIDINE;

ANIMAL EXPERIMENT; ARTICLE; BRAIN BLOOD FLOW; BRAIN ISCHEMIA; CONTROLLED STUDY; DRUG EFFECT; DRUG USE; INTRAPERITONEAL DRUG ADMINISTRATION; NEUROTRANSMISSION; NONHUMAN; RAT;

ADRENERGIC ALPHA-AGONISTS; ANIMALS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY TEMPERATURE; CARBON DIOXIDE; CEREBROVASCULAR CIRCULATION; CLONIDINE; HEMATOCRIT; ISCHEMIC ATTACK, TRANSIENT; MALE; OXYGEN; PULSE; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 0032169760     PISSN: 00903019     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-3019(97)00500-4     Document Type: Article

References (60)

1. 1. Chan PH, Fishman RA, Lee JL, Candelise L. Effects on excitatory neurotransmitter amino acids on swelling of rat brain cortical slices. J Neurochem 1979;33: 1309-15.
2. 2. Cooper JR, Bloom FE, Roth RH. Excitatory amino acids. In: The biochemical basis of neuropharmacology. New York: Oxford University Press, 1991:133-8.
3. 3. Davies J, Johnston SE, Hill DR, Quinlan JE. Tizanidine (DS 103-282), a centrally acting muscle relaxant, selectively depresses excitation of feline dorsal horn neurons to noxious peripheral stimuli by an action at α2-adrenoceptors. Neurosci Lett 1984;48:197-202.
4. 4. Davies J. Selective depression of synaptic transmission of spinal neurons in the cat by a new centrally acting muscle relaxant, 5-chloro-4-(2-imidazolin-2-yl-amino)-2,1,3-benzothiazole (DS 103-282). Brit J Pharmacol 1982;76:473-81.
5. 5. De Sarro GB, De Sarro A. Antagonists of adenosine and alfa-2-adrenoreceptors reverse the anticonvulsant effects of Tizanidine in DBA/2 mice. Neuropharmacology 1989;28:211-5.
6. 6. Fromm GH, Aumendado D, Terrence CF. A clinical and experimental investigation of effects of Tizanidine in trigeminal neuralgia. Pain 1993;53:265-71.
7. 7. Fryda-Kaurimsky Z, Mueller-Fassbender H. Tizanidine (DS 103-282) in the treatment of acute paravertebral muscle spasm: A controlled trial comparing Tizanidine and diazepam. J Int Med Res 1981;9:501-5.
8. 8. Greennamyre JT. The role of glutamate in transmission and in neurologic disease. Arch Neurol 1986;45: 1058-64.
9. 9. Hagberg H, Lehmann A, Sandberg M, Nystrom B, Jacobson I, Hamberger A. Ischemia-induced shift of inhibitory and excitatory amino acids from intracellular to extracellular compartments. J Cereb Blood Flow Metab 1985;413:5-12.
10. 10. Hassen N, McLellan DL. Double blind comparison of single doses of DS 103-282, baclofen and placebo for supression of spasticity. J Neurol Neurosurg Psychiat 1980;43:1132-6.
11. 11. Hiramatsu K, Kassel NF, Goto Y, Soleau S, Lee KS. A reproducible model of reversible, focal, neocortical ischemia in Sprague-Dawley rat. Acta Neurochir (Wien) 1993;120:66-71.
12. 12. Hossmann KA, Kleihues P. Reversibility of ischemic brain damage. Arch Neurol 1973;29:375-84.
13. 13. Hutchinson DR. Modified release tizanidine: a review. J Int Med Res 1989;17:565-73.
14. 14. Ito U, Ohno K, Nakamura R. Brain edema during ischemia and after restoration of blood flow. Measurement of water, sodium, potassium content and plasma protein permeability. Stroke 1979;10:542-7.
15. 15. Kameyama T, Nabeshima T, Sugimoto A, Matsuno K, Yamada S. Antinoceptive action of Tizanidine in mice and rats. Naunyn-Schmiedeberg's Arch Pharmacol 1985;330:93-6.
16. 16. Kameyama T, Nabeshima T, Yamada S. Hypothermic and anti-inflammatory effects of tizanidine. Oyo Yakuri (Pharmacometrics) 1986;30:867-71.
17. 17. Kolluri VR, Lakshmi GY. Changes in regional levels of putative neurotransmitter amino acids in brain under unilateral forebrain ischemia. Neurochem-Res. 1989; 14:621-5.
18. 18. Koyuncuoǧlu H. The combination of Tizanidine markedly improves the treatment with dextromethorphan of heroin addicted outpatients. International Journal of Clin Pharmacol Therapeut 1995;33:13-19.
19. 19. Koyuncuoǧlu H, Aricioǧlu F, Üresin Y, Dizdar Y, Esin Y. Effect of Tizanidine morphine physical dependence: attenuation and intensification. Pharmacology Biochemistry and Behavior. 1992;42:693-8.
20. 20. Maeda-Hagiwara M, Watanabe H, Kanaoka R, Watanabe K. Influence of clonidine and a new related imidazoline derivative (Tizanidine) on rat gastric mucosa. Pharmacology 1986;32:109-13.
21. 21. Mathias CJ, Luckitt J, Desai P, Baker H, Masri WE, Frankel HS. Pharmacodynamics and pharmacokinetics of the oral antispastic agent Tizanidine in patients with spinal cord injury. J Rehabil Res Dev 1989;26:9-16.
22. 22. Maze M, Tranquilli W. Alpha-2 adrenoceptor agonists: Defining the role in clinical anesthesia. Anesthesiology 1991;74:581-605.
23. 23. McCarthy R, Kroin JS, Lubenow TR, Penn RD, Ivankovich AD. Effect of intrathecal Tizanidine on antinociception and blood pressure in the rat. Pain 1990;40: 333-8.
24. 24. Medici M, Pebet M, Ciblis D. A double-blind, long-term study of Tizanidine ('Sirdalud') in spasticity due to cerebrovascular lesions. Curr Med Res Opin 1989;11: 398-407.
25. 25. Muramatsu I, Kigoshi S. Tizanidine may discriminate between imidazoline-receptors and α 2-adrenoceptors. Japanese Journal of Pharmacology 1992:59;457-9.
26. 26. Müller H, Zierski J. Clinical experience with spinal morphine, midazolam and Tizanidine in spasticity. In: Müller H, Zierski J, Penn RD, eds. Local-spinal therapy of spasticity. Berlin: Springer-Verlag, 1988:143-50.
27. 27. Nab HW, Hommes OR. Depression associated with tizanidine. Brit Med J 1987;295:612-3.
28. 28. Nabeshima T, Yamada S, Sugitomo A, Matsuno K, Kameyama T. Comparison of Tizanidine and morphine with regard to tolerance-developing ability to antinociceptive action. Pharmacol Biochem Behav 1986;25:835-41.
29. 29. Nabeshima T, Matsuno K, Kameyama T. Involvement of spinal and supraspinal structures in tizanidine-induced antinociceptive action. Neurosci Lett 1986; 63:1-3.
30. 30. Nabeshima T, Matsuno K, Sugimoto A, Kameyama T. Antinociceptive activity induced by Tizanidine and α adrenoreceptors. Neuropharmacology 1987;26: 1453-5.
31. 31. Nedergaard M. Mechanisms of brain damage in focal cerebral ischemia. Acta Neurol Scand 1988;77:81-101.
32. 32. Nishigaya K, Yoshida Y, Sasuga M, Nukui H, Ooneda G. Effect of recirculation on exacerbation of ischemic vascular lesions in rat brain. Stroke 1991;22: 635-42.
33. 33. Noguchi K. Clinical effects of Tizanidine on neck-shoulder-arm syndrome and low back pain. Shinryo To Shinyaku (Med.Consult, and New Remedies) 1985: 22:2353-64.
34. 34. Novack GD. Studies on the efficacy and depressant potential of muscle relaxants in mice. Drug Dev Res 1982;2:383-6.
35. 35. Ono H, Matsumoto K, Kato K, Kato F, Miyamoto M, Mori T, Nakamura T, Oka J, Fukuda H. Effects of tizanidine, a centrally acting muscle relaxant, on motor systems. Gen Pharmacol 1986;17:137-42.
36. 36. Ono H, Fukushima C, Fukuda H. Effect of the centrally acting muscle relaxant Tizanidine on spinal reflexes: involvement on descending noradrenergic systems. Japan J Pharmacol 1993;62:357-62.
37. 37. Özyurt E, Graham DI, Park CK, Nehls DG, Teasdale GM, McCulloch J. Protective effects of the NMDA antagonist, MK-801, on focal ischemic brain damage, In: Ginsberg MD, Dietrich WD, eds. Cerebrovascular diseases-sixteenth research (Princeton) conference. New York: Raven Press, 1989:65-72.
38. 38. Rice GPA. Pharmacotherapy on spasticity: some theoretical and practical considerations. Canad J Neurol Sci 1987;14:510-2.
39. 39. Rothman S. Synaptic release of EAA neurotransmitter mediates anoxic neuronal death. J Neurosci 1984;4: 1884-92.
40. 40. Rothman S, Olney JW. Excitotoxicity and the NMDA receptor. TINS 1987;10:299-302.
41. 41. Rothman S, Olney JW. Glutamate and pathophysiology of hypoxic-ischemic brain damage. Ann Neurol 1986;19:105-12.
42. 42. Rothman S. Synaptic activity mediates death of hypoxic neurons. Science 1983;220:536-7.
43. 43. Sandberg M, Butcher SP, Hagberg H. Extracellular overflow of neuroactive amino acids during severe insulin-induced hypoglycemia: in vivo analysis of the rat hippocampus. J Neurochem 1986;47:178-85.
44. 44. Sato K, Chou Y, Chang KH, Aoki M, Imanishi N, Shibuya T. Pharmacological studies on a new central muscle relaxant tizanidine. I. Study on behavioral pharmacology J Tokyo Med Coll 1985;43:1093-9.
45. 45. Sato K, Shih HC, Hong YL, Saruhara T, Hara I, Shibuya T. Pharmacological studies on a new central muscle relaxant tizanidine. II. Study on general pharmacology. J Tokyo Med Coll 1985;43:1100-6.
46. 46. Sato K, Hong YL, Shih HC, Saruhara T, Aoki M, Shibuya T. Pharmacological studies on a new central muscle relaxant tizanidine. III. Supplementary study on general pharmacology. J Tokyo Med Coll 1986;44: 10-15.
47. 47. Sayers AC, Bürki H, Eichenberger E. The pharmacology of 5-chloro-4-(2-imidazolin-2-yl-amino)-2,1,3-benzothiazole (DS 103-282), a novel myotonolytic agent. Arzneimittel-Forsh 1980;30:793-803.
48. 48. Schwarz M, Klockgether T, Turski L, Sonntag VKH. Intrathecal injection of antispastic drugs in rats: muscle relaxant action of midazolam, baclofen, 2-Aminophosphonoheptanoic acid (APT) and tizanidine. In: Müller H, Zierski J, Penn RD, eds. Local-spinal therapy of spasticity. Berlin: Springer-Verlag, 1988:65-79.
49. 49. Siesjö BK. Mechanisms of ischemic brain damage. Crit Care Med 1988;16:954-63.
50. 50. Siesjö BK. Pathophysiology and treatment of focal cerebral ischemia, Part I: Pathophysiology. J Neurosurg 1992;77:169-94.
51. 51. Siesjö BK. Pathophysiology and treatment of focal cerebral ischemia, Part II: Mechanism of damage and treatment. J Neurosurg 1992;77:337-54.
52. 52. Simbulan DS, Kumazawa T. Cardio-vascular effects of Tizanidine in the intact and denervated cat. Environm Med 1991;35:63-6.
53. 53. Sundt TM Jr, Grant WC, Garcia JH. Restoration of middle cerebral artery flow in experimental infarction. J Neurosurg 1969;31:311-22.
54. 54. Takayanagi I, Konno F. Pharmacological actions of tizanidine, a centrally acting muscle relaxant, on various smooth muscle organs. Oyo Yakuri (Pharmacometrics) 1985;29:493-500.
55. 55. Tamura A, Graham DI, McCulloch J, Teasdale GM. Focal cerebral ischemia in the rat I: Description of technique and early neuropathological consequences following middle cerebral artery occlusion. J Cereb Blood Flow Metab 1981;1:53-60.
56. 56. Tse FLS, Jaffe JM, Bhuta S. Pharmacokinetics of orally administered Tizanidine in healthy volunteers. Fundam Clin Pharmacol 1987;1:479-88.
57. 57. Vilming ST, Lyberg T, Lataste X. Tizanidine in the management of trigeminal neuralgia. Cephalalgia 1986;6:181-2.
58. 58. Wieloch T. Hypoglycemia-induced neuronal damage prevented by an N-methyl-D-aspartate antagonist. Science 1985;681-3.
59. 59. Yang G, Chan P, Chen SF, Babuna OA, Simon RP, Weinstein PR. Reduction of vasogenic edema and infarction by MK-801 in rats after temporary focal cerebral ischemia. Neurosurgery 1994;34:339-45.
60. 60. Zirh TA, Pamir MN, Özek MM, Sav A, Onat FA. Standardizable model of focal cerebral ischaemia in normotensive rats. J Clin Neurosci 1995;2:245-51.